Inside the PsO Pipeline: Oruka’s Long-acting Injectable Performs Well in Phase 2a Study

Oruka Therapeutics’ long-acting ORKA-001 is showing promise in moderate-to-severe plaque psoriasis, according to interim results from the EVERLAST-A Phase 2a trial.